Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 300282
                    [Title] => New hepa B treatment outdoes standard care
                    [Summary] => A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care. 


A study was conducted among patients with HbeAG positive hepatitis B, the subtype of the disease which affects majority of hepatitis B patients worldwide.


                    [DatePublished] => 2005-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

DR. GEORGE LAU

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 300282
                    [Title] => New hepa B treatment outdoes standard care
                    [Summary] => A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care. 


A study was conducted among patients with HbeAG positive hepatitis B, the subtype of the disease which affects majority of hepatitis B patients worldwide.


                    [DatePublished] => 2005-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

New hepa B treatment outdoes standard care

October 6, 2005 - 12:00am

A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care....

Science and Environment